Alimera expands distribution pact for eye drug implant Iluvien to Nordic region
fotostorm
- Alimera Sciences (NASDAQ:ALIM) said it expanded an agreement with its distributor partner Horus Pharma for Iluvien to include Nordic countries
- The companies will expand their partnership beyond France, Belgium, Luxembourg and the Netherlands to boost commercialization efforts for Iluvien for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in the Nordic countries of Denmark, Finland, Norway and Sweden.
- "Our team is delighted to develop and expand its collaboration with Alimera, as we are thrilled with the success of ILUVIEN in France and Benelux," said Horus CEO Claude Claret. "ILUVIEN has become an asset for us, helping to drive our expansion throughout Europe."
- Iluvien is an intravitreal implant that is injected into the back of the eye releasing sub-microgram levels of fluocinolone acetonide. It is approved in the U.S. to treat certain patients with DME.